Results 121 to 130 of about 6,619,981 (269)

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers [PDF]

, 2023
Subir Biswas, Gunjan Mandal, Carmen M. Anadon, Ricardo A. Chaurio, Luis Lopez‐Bailon, Mate Z. Nagy, Jessica A. Mine, Kay Hänggi, Kimberly B. Sprenger, Patrick Innamarato, Carly M. Harro, John J. Powers, Joseph Johnson, Bin Fang, Mostafa Eysha, Xiaolin Nan, Roger Li, Bradford A. Perez, Tyler J. Curiel, Xiaoqing Yu, Paulo C. Rodrı́guez, José R. Conejo-García   +21 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer

, 2011
Charles B. Simone, David Ly, Tu Dan, John Ondos, Holly Ning, Arnaud Belard, John O’Connell, Robert W. Miller, Nicole L. Simone   +8 more
openalex   +2 more sources

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients [PDF]

, 2012
Neil L. Berinstein, Mohan Karkada, Michael A. Morse, John Nemunaitis, Gurkamal Chatta, Howard L. Kaufman, Kunle Odunsi, Rita Nigam, Leeladhar Sammatur, Lisa D. MacDonald, Genevieve Weir, Marianne M. Stanford, Marc Mansour   +12 more
openalex   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer

, 2016
Jonathan Welti, Daniel Nava Rodrigues, Adam Sharp, Shihua Sun, David Lorente, Ruth Riisnaes, Ines Figueiredo, Zafeiris Zafeiriou, Pasquale Rescigno, Johann S. de Bono, Stephen R. Plymate   +10 more
openalex   +1 more source

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer [PDF]

, 2021
Noori A.M. Guman, Roos J. van Geffen, Frits I. Mulder, Thijs F. van Haaps, Vahram Hovsepjan, Mariëtte Labots, Geert A. Cirkel, Filip De Vos, Albert J. ten Tije, Laurens V. Beerepoot, Vivianne C. G. Tjan‐Heijnen, Hanneke W.M. van Laarhoven, Paul Hamberg, Annelie Vulink, Maartje Los, Aeilko H. Zwinderman, Bart Ferwerda, Martijn P. Lolkema, Neeltje Steeghs, Harry R. Büller, Pieter W. Kamphuisen, Nick van Es   +21 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source